Southcoast Health Cancer Center Fairhaven

Southcoast Health

Neoplasm Metastasis

Lung Cancer

Urologic Cancer

Colonic Cancer

Melanoma

Head and Neck Cancer

Esophageal Cancer

Pancreatic Cancer

Breast Cancer

Cancer

Niraparib

Tempus AI

condition

Endometrial Cancer

allSponsorName

GlaxoSmithKline (GSK)

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

Southcoast Health | Southcoast Health Cancer Center Fairhaven

Site insights

Work at this site?

Active trials

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (PAVO)

Trial sponsors